Cal-101, now called GS-1101, is an oral drug (technically a PK13-delta inhibitor) developed by Calistoga Pharmaceuticals showing great promise for the treatment of certain non-Hodgkin’s lymphomas and chronic lymphocytic leukemias. Calistoga was taken over by Gilead Sciences which is now advancing the experimental drug through Phase 3 clinical trials.
We have heard very positive things about the performance of GS-1101. Unfortunately, Gilead did not respond to our request for additional non-confidential information, so we will do other research and post additional perspectives here as we are able. There are a number of clinical trials open for enrollment, and you can do a little research on your own at the NCI’s clinical trials site: http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=11431626